EUVIMEDEUVIMED entdecken
Open Access

Epidemiology of Infections in Lung Transplant Recipients Treated With Belatacept

Madeleine R Heldman iD, Jennifer L Saullo iD, Brandon M Menachem, Julia A Messina iD, Sana Arif, Julie M Steinbrink iD, Patrick C K Tam iD, Manuela Carugati iD, Cameron R Wolfe iD, Arthur W Baker iD, Eileen K Maziarz iD

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.14403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Madeleine R Heldman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Abatacept, Lung Transplantation, Immunosuppressive Agents, Graft Rejection. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: and Infectious Diseases, International Society of Lung Transplantation, National Institute of Allergy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Belatacept is a costimulatory blocker that can be used to prevent and treat rejection in lung transplant recipients (LuTRs). The epidemiology of infections in belatacept‐treated LuTRs has not been systematically evaluated.

Methods

We performed a single‐center retrospective study of all adult LuTRs who received belatacept as prevention or treatment of antibody‐mediated rejection (desensitization) or as part of maintenance immunosuppression from January 1, 2011, to June 30, 2022. We assessed the epidemiology of infections that occurred within 12 months following the first belatacept dose.

Results

Fifty‐two LuTRs received at least one dose of belatacept as either desensitization (n = 32) or maintenance immunosuppression ( n = 20). Among 45 patients who were cytomegalovirus (CMV) donor and/or recipient seropositive, nine (20%) developed CMV infection. Seven (77%) CMV infections occurred despite valganciclovir prophylaxis and four (44%) were associated with antiviral resistance. Three (6%) LuTRs developed Epstein‐Barr virus (EBV) associated post‐transplant lymphoproliferative disorder (PTLD). Twenty‐five (48%) LuTRs developed 43 bacterial infections and five (10%) developed proven or probable invasive fungal disease. Incidence rates of viral, bacterial, and fungal infections were similar between the desensitization and maintenance groups: incidence rate ratios (95% confidence interval) were 0.70 (0.32–1.57), 1.31 (0.70–2.46), and 2.82 (0.31–25.2), respectively. Infection/PTLD prompted belatacept discontinuation in eight (15%) patients.

Conclusions

In the first year after belatacept initiation, LuTRs commonly developed CMV infections, EBV+ PTLD, and bacterial infections. Multicenter collaborations are needed to better understand infection risks in LuTRs treated with belatacept. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptLung TransplantationImmunosuppressive AgentsGraft RejectionBacterial InfectionsHumansMaleFemaleRetrospective StudiesMiddle AgedAdultTransplant RecipientsCytomegalovirus InfectionsAgedIncidence

Stichwörter der Autor:innen

Cytomegalovirusbelataceptimmunosuppressioninfectionslung transplant

Substanzen

AbataceptImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA.
  • Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

ORCID-Profile: Madeleine R Heldman, Jennifer L Saullo, Julia A Messina, Julie M Steinbrink, Patrick C K Tam, Manuela Carugati, Cameron R Wolfe, Arthur W Baker, Eileen K Maziarz

Förderung

  • and Infectious Diseases
  • International Society of Lung Transplantation
  • National Institute of Allergy
  • NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Heldman, M. R., Saullo, J. L., Menachem, B. M., Messina, J. A., Arif, S., Steinbrink, J. M., Tam, P. C. K., Carugati, M., Wolfe, C. R., Baker, A. W., & Maziarz, E. K. (2025). Epidemiology of Infections in Lung Transplant Recipients Treated With Belatacept. Transplant Infectious Disease. https://doi.org/10.1111/tid.14403

Vancouver

Heldman MR, Saullo JL, Menachem BM, Messina JA, Arif S, Steinbrink JM, et al. Epidemiology of Infections in Lung Transplant Recipients Treated With Belatacept. Transplant Infectious Disease. 2025. doi:10.1111/tid.14403

BibTeX
@article{Heldman2025,
  author = {Heldman, Madeleine R and Saullo, Jennifer L and Menachem, Brandon M and Messina, Julia A and Arif, Sana and Steinbrink, Julie M and Tam, Patrick C K and Carugati, Manuela and Wolfe, Cameron R and Baker, Arthur W and Maziarz, Eileen K},
  title = {Epidemiology of Infections in Lung Transplant Recipients Treated With Belatacept},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.14403}
}
Kostenlos starten →